NMN oral intake shown safe and well metabolised for the first time – Oriental Yeast funded trial
A trial involving healthy Japanese men revealed for the first time that a single dose of nicotinamide mononucleotide (NMN) is safe for consumption and is effectively metabolised by the body.
The study, published in Endocrine Journal, was conducted by researchers from the Keio University School of Medicine and a number of industry research labs.
NMN is an intermediate compound of nicotinamide adenine dinucleotide (NAD+). Administration of NMN has been shown to mitigate ageing-related dysfunctions.
The researchers believed that this is the first human study to examine the safety of NMN oral administration.
Top 10 most read nutrition research of 2020 Egg white and whey protein key to boosting male fertility, but slash ‘healthy’ fats and McDonald's muffins ‘Disconcerting discovery’: Study shows plant-based milk lacking in calcium, protein, vitamins NMN oral intake shown safe and well metabolised for the first time – Oriental Yeast funded trial Hot findings: Higher chilli intake linked to lower chronic kidney disease in Chinese adults Korean red ginseng reduces fatigue without increasing ‘heatiness’ – Chinese study Big in Japan: Probiotics most popular non-vitamin / mineral pick for children – major survey Options matter: Nestle Philippines study shows children drinking age-appropriate milk have higher micronutrient intake 'Naturally good': Natural astaxanthin top form for functionality and antioxidant activity - Review China formula ‘contamination’: Mineral oil hydrocarbon found in all goat-dairy products tested Probiotics with magnesium oxide effective in managing constipation in children – BioGaia study